Spirometers by Type (Table Top and Portable), Technology (Volume Measurement and Flow Measurement), Application (Asthma, Chronic Obstructive Pulmonary Disease [COPD], Cystic Fibrosis, and Others), End-User (Hospitals, Clinics, and Home Care), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising burden of respiratory diseases, the surge in cigarette smoking, increasing awareness and screening programs, and increase in product launches and approvals by key market players across the globe.
The spirometer market will grow at a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 1.80 billion by 2030. The market for spirometer is set to experience significant growth driven by several key factors. Firstly, the rising burden of respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, underscores the need for effective diagnostic and monitoring tools, thereby increasing the demand for spirometer. The surge in cigarette smoking further exacerbates respiratory conditions, heightening the necessity for routine lung function testing to manage and prevent disease progression. Additionally, increasing awareness about respiratory health and the implementation of widespread screening programs are fostering early detection and intervention, which fuels the adoption of spirometry as a standard diagnostic tool. Furthermore, the market is being bolstered by a rise in product launches and approvals from key market players, who are continuously innovating and introducing advanced spirometry devices with improved features and technology. These factors are expected to collectively contribute to the expanding market for spirometer during the forecast period from 2024 to 2030.
Additionally, as per the recent data provided by the Global Burden of Disease (2023), approximately, 1 in 20 people globally suffers from chronic respiratory diseases.
Furthermore, as per the recent data provided by the World Health Organization (2023), smoking was a major cause of chronic obstructive pulmonary disease, a common lung condition that led to breathing difficulties and claimed over 3 million lives annually. Approximately 392 million people have COPD, with about 75% living in low- and middle-income countries. In high-income countries, tobacco smoking was responsible for over 70% of COPD cases.
As the incidence of respiratory disorders rises, driven largely by smoking and environmental factors, there is a heightened need for Spirometers, which are critical in delivering medication directly to the lungs for effective symptom relief and disease management.
Additionally, as per the recent data provided by GLOBOCAN, in 2022, globally the estimated new cases of trachea, bronchus, and lung cancer was 2.48 million, and the projections are expected to rise by 4.25 million by the year 2045. COPD, a progressive respiratory condition primarily caused by smoking, requires regular assessment of lung function to manage symptoms and track disease progression. As COPD prevalence rises, healthcare providers are increasingly relying on spirometer to evaluate lung capacity and airflow obstruction, making these devices essential for both diagnosis and ongoing management. Similarly, the surge in smoking rates contributes to a higher incidence of respiratory disorders, including COPD, which in turn drives the need for spirometry tests. Smokers and former smokers are often targeted for regular lung function screening to detect early signs of damage and prevent further deterioration.
Additionally, companies are amplifying their production of spirometer and securing regulatory approvals, thereby strategically expanding their market presence and driving further growth. For instance, in January 2024, NuvoAir Medical announced that its innovative Air Next Spirometer had received formal 510(k) clearance for in-home use as a full spirometer. This approval allowed NuvoAir to scale and expand its clinical operations, ensuring that no patient with heart or lung conditions was left behind.
Moreover, the success of the clinical trial on spirometry gave a significant boost to the market, enhancing its growth prospects and driving increased interest and investment. For instance, in January 2023, Koneksa, a healthcare technology company that developed evidence-based digital biomarkers, announced the launch of a clinical study. The study compared the treatment effects of at-home mobile spirometry using digital biomarkers with in-clinic spirometry in patients with moderate asthma who were on long-acting beta-agonist (LABA) treatment.
Thus, the factors mentioned above are likely to boost the market of spirometers during the forecasted period.
However, the availability of alternative devices such as peak flow meters, capnometers, imagining techniques, and pulse oximeters may hinder the future market of spirometers.
In the type segment of the spirometer market, the portable spirometer is expected to hold a significant share in 2023. Portable spirometers are significantly boosting the overall spirometer market by enhancing accessibility and convenience for both patients and healthcare providers. These compact, handheld devices allow for real-time monitoring of lung function outside of traditional clinical settings, enabling patients to conduct tests at home or on the go. This increased accessibility is particularly valuable for managing chronic respiratory conditions like asthma and COPD, where regular monitoring is crucial. Portable spirometers also facilitate early detection and intervention, as patients can perform frequent tests without needing to visit a healthcare facility. Additionally, advancements in connectivity and integration with mobile health apps have enabled seamless data sharing with healthcare providers, improving remote patient management and personalized care. The growing adoption of portable spirometers reflects a shift towards more proactive and patient-centered healthcare, driving market growth as these devices become an integral part of routine respiratory health management.
In addition, new product launches are also likely to upsurge the global spirometer market during the forecasted period. For instance, in November 2021, Cipla announced the launch of Spirofy®, India's first pneumotach-based portable, wireless spirometer, on World COPD Day. With this launch, the company aimed to revolutionize the diagnosis of Obstructive Airway Disease (OAD) and strengthen its position as a leader in lung health in India. This was part of the Company’s LungAttack campaign, which sought to raise awareness about COPD and promote early diagnosis. Additionally, a shift in trend from table-top to portable devices will offer assistance in remote settings. This will increase the acceptance of spirometers for patients.
Hence, all the above-mentioned factors are expected to generate considerable revenue for the segment pushing the overall growth of the global spirometer market during the forecast period.
According to the recent data and stats provided by the American Lung Association (2024), in 2022, among children, asthma was more common in males accounting for 7.0% of the population in the United States and 5.4% in females. Additionally, as per the same source, asthma among adults is 10.8% for females and 6.5% for females across the region of the United States. Asthma management requires regular monitoring of lung function to adjust treatment plans and prevent exacerbations. Spirometers allow patients to track their lung function over time, providing critical data to healthcare providers for optimizing treatment strategies. This continuous need for monitoring drives the market for both in-clinic and portable spirometers.
Additionally, as per the data provided by the Centre for Disease Control and Prevention (2024), in 2022, 4.6% of adults had been diagnosed with COPD, emphysema, or chronic bronchitis in the United States.
Furthermore, as per the recent data and stats provided by the Centre for Disease Control and Prevention (2023), in 2021, approximately 11.5% of U.S. adults aged 18 and older smoked cigarettes, totaling around 28.3 million smokers. At that time, over 16 million Americans were living with a smoking-related disease. The spirometer market is significantly boosted by the increasing prevalence of chronic respiratory conditions such as COPD, emphysema, and chronic bronchitis, alongside rising smoking rates. These conditions, which are often exacerbated by smoking, require regular and accurate monitoring of lung function for effective management and treatment. Spirometers are essential tools for diagnosing and tracking these diseases, as they measure vital lung parameters such as airflow and lung volume.
The increasing number of product development activities in the region is further going to accelerate the growth of the spirometer market. For instance, in August 2021, Roundworks Technologies Private Limited announced the approval of 510(k) for its Alveoair Digital Spirometer. Alveoair® is a personal spirometer designed for asthma, COPD, cystic fibrosis, and ILD patients to help quantify their lung health.
Furthermore, in March 2023, Clario, a healthcare research technology company known for its endpoint technology solutions for clinical trials, announced a partnership with the technology startup ArtiQ. This collaboration aimed to improve the accuracy of respiratory clinical trials that require spirometry data. The partnership allowed for AI-based reviews of spirometry data collected on the Clario platform.
Therefore, the above-mentioned factors are expected to bolster the growth of the spirometer market in North America during the forecast period.
This product will be delivered within 2 business days.
The spirometer market will grow at a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 1.80 billion by 2030. The market for spirometer is set to experience significant growth driven by several key factors. Firstly, the rising burden of respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, underscores the need for effective diagnostic and monitoring tools, thereby increasing the demand for spirometer. The surge in cigarette smoking further exacerbates respiratory conditions, heightening the necessity for routine lung function testing to manage and prevent disease progression. Additionally, increasing awareness about respiratory health and the implementation of widespread screening programs are fostering early detection and intervention, which fuels the adoption of spirometry as a standard diagnostic tool. Furthermore, the market is being bolstered by a rise in product launches and approvals from key market players, who are continuously innovating and introducing advanced spirometry devices with improved features and technology. These factors are expected to collectively contribute to the expanding market for spirometer during the forecast period from 2024 to 2030.
Spirometers Market Dynamics:
According to the latest data provided by the Australian Institute of Health and Welfare, in 2022, around 8.5 million (34%) people in Australia were estimated to have chronic respiratory conditions.Additionally, as per the recent data provided by the Global Burden of Disease (2023), approximately, 1 in 20 people globally suffers from chronic respiratory diseases.
Furthermore, as per the recent data provided by the World Health Organization (2023), smoking was a major cause of chronic obstructive pulmonary disease, a common lung condition that led to breathing difficulties and claimed over 3 million lives annually. Approximately 392 million people have COPD, with about 75% living in low- and middle-income countries. In high-income countries, tobacco smoking was responsible for over 70% of COPD cases.
As the incidence of respiratory disorders rises, driven largely by smoking and environmental factors, there is a heightened need for Spirometers, which are critical in delivering medication directly to the lungs for effective symptom relief and disease management.
Additionally, as per the recent data provided by GLOBOCAN, in 2022, globally the estimated new cases of trachea, bronchus, and lung cancer was 2.48 million, and the projections are expected to rise by 4.25 million by the year 2045. COPD, a progressive respiratory condition primarily caused by smoking, requires regular assessment of lung function to manage symptoms and track disease progression. As COPD prevalence rises, healthcare providers are increasingly relying on spirometer to evaluate lung capacity and airflow obstruction, making these devices essential for both diagnosis and ongoing management. Similarly, the surge in smoking rates contributes to a higher incidence of respiratory disorders, including COPD, which in turn drives the need for spirometry tests. Smokers and former smokers are often targeted for regular lung function screening to detect early signs of damage and prevent further deterioration.
Additionally, companies are amplifying their production of spirometer and securing regulatory approvals, thereby strategically expanding their market presence and driving further growth. For instance, in January 2024, NuvoAir Medical announced that its innovative Air Next Spirometer had received formal 510(k) clearance for in-home use as a full spirometer. This approval allowed NuvoAir to scale and expand its clinical operations, ensuring that no patient with heart or lung conditions was left behind.
Moreover, the success of the clinical trial on spirometry gave a significant boost to the market, enhancing its growth prospects and driving increased interest and investment. For instance, in January 2023, Koneksa, a healthcare technology company that developed evidence-based digital biomarkers, announced the launch of a clinical study. The study compared the treatment effects of at-home mobile spirometry using digital biomarkers with in-clinic spirometry in patients with moderate asthma who were on long-acting beta-agonist (LABA) treatment.
Thus, the factors mentioned above are likely to boost the market of spirometers during the forecasted period.
However, the availability of alternative devices such as peak flow meters, capnometers, imagining techniques, and pulse oximeters may hinder the future market of spirometers.
Spirometers Market Segment Analysis:
Spirometers by Type (Table Top and Portable), Technology (Volume Measurement and Flow Measurement), Application (Asthma, Chronic Obstructive Pulmonary Disease [COPD], Cystic Fibrosis, and Others), End-User (Hospitals, Clinics, and Home Care), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)In the type segment of the spirometer market, the portable spirometer is expected to hold a significant share in 2023. Portable spirometers are significantly boosting the overall spirometer market by enhancing accessibility and convenience for both patients and healthcare providers. These compact, handheld devices allow for real-time monitoring of lung function outside of traditional clinical settings, enabling patients to conduct tests at home or on the go. This increased accessibility is particularly valuable for managing chronic respiratory conditions like asthma and COPD, where regular monitoring is crucial. Portable spirometers also facilitate early detection and intervention, as patients can perform frequent tests without needing to visit a healthcare facility. Additionally, advancements in connectivity and integration with mobile health apps have enabled seamless data sharing with healthcare providers, improving remote patient management and personalized care. The growing adoption of portable spirometers reflects a shift towards more proactive and patient-centered healthcare, driving market growth as these devices become an integral part of routine respiratory health management.
In addition, new product launches are also likely to upsurge the global spirometer market during the forecasted period. For instance, in November 2021, Cipla announced the launch of Spirofy®, India's first pneumotach-based portable, wireless spirometer, on World COPD Day. With this launch, the company aimed to revolutionize the diagnosis of Obstructive Airway Disease (OAD) and strengthen its position as a leader in lung health in India. This was part of the Company’s LungAttack campaign, which sought to raise awareness about COPD and promote early diagnosis. Additionally, a shift in trend from table-top to portable devices will offer assistance in remote settings. This will increase the acceptance of spirometers for patients.
Hence, all the above-mentioned factors are expected to generate considerable revenue for the segment pushing the overall growth of the global spirometer market during the forecast period.
North America is expected to dominate the overall spirometer market:
North America is expected to account for the highest proportion of the spirometer market in 2023, out of all regions. This can be ascribed to the increasing prevalence of respiratory disease across the region, the increase in technological advancement, the surge in cigarette smoking, the increase in government initiatives coupled with increased awareness programs for respiratory disorders, and the presence of key market players engaged in merger, acquisition, product launches, and other market activities across the region are expected to escalate the market of Spirometers during the forecast period.According to the recent data and stats provided by the American Lung Association (2024), in 2022, among children, asthma was more common in males accounting for 7.0% of the population in the United States and 5.4% in females. Additionally, as per the same source, asthma among adults is 10.8% for females and 6.5% for females across the region of the United States. Asthma management requires regular monitoring of lung function to adjust treatment plans and prevent exacerbations. Spirometers allow patients to track their lung function over time, providing critical data to healthcare providers for optimizing treatment strategies. This continuous need for monitoring drives the market for both in-clinic and portable spirometers.
Additionally, as per the data provided by the Centre for Disease Control and Prevention (2024), in 2022, 4.6% of adults had been diagnosed with COPD, emphysema, or chronic bronchitis in the United States.
Furthermore, as per the recent data and stats provided by the Centre for Disease Control and Prevention (2023), in 2021, approximately 11.5% of U.S. adults aged 18 and older smoked cigarettes, totaling around 28.3 million smokers. At that time, over 16 million Americans were living with a smoking-related disease. The spirometer market is significantly boosted by the increasing prevalence of chronic respiratory conditions such as COPD, emphysema, and chronic bronchitis, alongside rising smoking rates. These conditions, which are often exacerbated by smoking, require regular and accurate monitoring of lung function for effective management and treatment. Spirometers are essential tools for diagnosing and tracking these diseases, as they measure vital lung parameters such as airflow and lung volume.
The increasing number of product development activities in the region is further going to accelerate the growth of the spirometer market. For instance, in August 2021, Roundworks Technologies Private Limited announced the approval of 510(k) for its Alveoair Digital Spirometer. Alveoair® is a personal spirometer designed for asthma, COPD, cystic fibrosis, and ILD patients to help quantify their lung health.
Furthermore, in March 2023, Clario, a healthcare research technology company known for its endpoint technology solutions for clinical trials, announced a partnership with the technology startup ArtiQ. This collaboration aimed to improve the accuracy of respiratory clinical trials that require spirometry data. The partnership allowed for AI-based reviews of spirometry data collected on the Clario platform.
Therefore, the above-mentioned factors are expected to bolster the growth of the spirometer market in North America during the forecast period.
Spirometers Market Key Players:
Some of the key market players operating in the Spirometers market include FUKUDA SANGYO CO., LTD., Midmark Corporation, CHEST M.I., Inc., KoKo PFT, Clarity Medical Pvt. Ltd., COSMED srl, Jones Medical Instrument Company, Baxter, Teleflex Incorporated, VYAIRE MEDICAL, INC., SIBEL, S.A.U., Medikro Oy, ICU Medical Inc., Vitalograph, Futuremed USA, Schiller AG, Aksia Group SGR S.p.A, CONTEC MEDICAL SYSTEMS CO., LTD, NDD Medical Technologies, MGC DIAGNOSTICS CORPORATION, and others.Recent Developmental Activities in the Spirometers Market:
- In September 2022, RxCap, Inc., a cloud-based remote monitoring company, and ZEPHYRx LLC, a provider of remote respiratory monitoring solutions, announced their partnership to integrate ZEPHYRx’s cloud spirometry platform with RxCap’s remote monitoring platform.
- In March 2022, KoKo, LLC, a software developer and medical device manufacturer, and MAGNET group, a purchasing organizations (GPO) company signed a three-year partnership contract that allows access to all of KoKo’s “gold standard” lung function diagnostics and software for spirometry, diffusion capacity, and PFT.
Key Takeaways From the Spirometers Market Report Study:
- Market size analysis for current spirometer size (2023), and market forecast for 6 years (2024 to 2030)
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
- Key companies dominating the spirometer market.
- Various opportunities available for the other competitors in the spirometer market space.
- What are the top-performing segments in 2023? How these segments will perform in 2030?
- Which are the top-performing regions and countries in the current spirometer market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for spirometer market growth in the coming future?
Target Audience who can be Benefited From This Spirometers Market Report Study:
- Spirometers product providers
- Research organizations and consulting companies
- Spirometers -related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in spirometer
- Various end-users who want to know more about the spirometer market and the latest technological developments in the spirometer market.
Frequently Asked Questions for the Spirometers Market:
1. What are spirometers?
The spirometer is a medical device that is used for performing spirometry tests to examine the function of the lungs. It is a very valuable tool for studying multiple respiratory problems such as asthma, chronic obstructive pulmonary disease (COPD), and others. It is also used to evaluate possible occupational pulmonary disorders and can be used to test lung functioning before surgery.2. What is the market for spirometers?
The spirometer market will grow at a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 1.80 billion by 2030.3. What are the drivers for the spirometer market?
The spirometer market is set to experience significant growth driven by several key factors. Firstly, the rising burden of respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, underscores the need for effective diagnostic and monitoring tools, thereby increasing the demand for spirometers. The surge in cigarette smoking further exacerbates respiratory conditions, heightening the necessity for routine lung function testing to manage and prevent disease progression. Additionally, increasing awareness about respiratory health and the implementation of widespread screening programs are fostering early detection and intervention, which fuels the adoption of spirometry as a standard diagnostic tool. Furthermore, the market is being bolstered by a rise in product launches and approvals from key market players, who are continuously innovating and introducing advanced spirometry devices with improved features and technology. These factors are expected to collectively contribute to the expanding market for spirometers during the forecast period from 2024 to 2030.4. Who are the key players operating in the spirometer market?
Some of the key market players operating in the Spirometers market include FUKUDA SANGYO CO., LTD., Midmark Corporation, CHEST M.I., Inc., KoKo PFT, Clarity Medical Pvt. Ltd., COSMED srl, Jones Medical Instrument Company, Baxter, Teleflex Incorporated, VYAIRE MEDICAL, INC., SIBEL, S.A.U., Medikro Oy, ICU Medical Inc., Vitalograph, Futuremed USA, Schiller AG, Aksia Group SGR S.p.A, CONTEC MEDICAL SYSTEMS CO., LTD, NDD Medical Technologies, MGC DIAGNOSTICS CORPORATION, and others.5. Which region has the highest share in the spirometer market?
North America is expected to account for the highest proportion of the spirometer market in 2023, out of all regions. This can be ascribed to the increasing prevalence of respiratory disease across the region, the increase in technological advancement, the surge in cigarette smoking, the increase in government initiatives coupled with increased awareness programs for respiratory disorders, and the presence of key market players engaged in merger, acquisition, product launches, and other market activities across the region are expected to escalate the market of Spirometers during the forecast period.This product will be delivered within 2 business days.
Table of Contents
1. Spirometers Market Report Introduction
2. Spirometers Market Executive Summary
4. Regulatory Analysis
5. Spirometers Market Key Factors Analysis
6. Spirometers Market Porter’s Five Forces Analysis
7. Spirometers Market Assessment
8. Spirometers Market Company and Product Profiles
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- FUKUDA SANGYO CO., LTD.
- Midmark Corporation
- CHEST M.I., Inc.
- KoKo PFT
- Clarity Medical Pvt. Ltd.
- COSMED srl
- Jones Medical Instrument Company
- Baxter
- Teleflex Incorporated
- VYAIRE MEDICAL, INC.
- SIBEL, S.A.U.
- Medikro Oy
- ICU Medical Inc.
- Vitalograph
- Futuremed USA
- Schiller AG
- Aksia Group SGR S.p.A
- CONTEC MEDICAL SYSTEMS CO., LTD
- NDD Medical Technologies
- MGC DIAGNOSTICS CORPORATION
